Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
Brian Grunau, David A. Goldfarb, Michael Asamoah-Boaheng, Liam Golding, Tracy L Kirkham, Paul A. Demers, Pascal M. Lavoie
Abstract
Standard dosing intervals for BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines are 21 and 28 days, respectively. 1 Data suggest improved effectiveness of ChAdOx1 adenoviral 2 and other nonreplicating vaccines 3 with increased dosing intervals, but little data exist for mRNA vaccines. This study investigated the immunogenicity of extended mRNA vaccine dosing intervals.
Topics & Concepts
MedicineImmunogenicitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyImmunologyInternal medicineOutbreakAntigenInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies